uniQure N.V.: insider trades · United States · SEC (Form 4)

About uniQure N.V.

uniQure N.V. (ticker: QURE) is a biotechnology company listed on the NASDAQ in the United States, making it part of the U.S. public-market universe for small- and mid-cap healthcare names. For French-speaking investors in France, Belgium, and Switzerland, the company is best viewed through the lens of gene therapy: it develops treatments for severe, rare, and high-unmet-need diseases using advanced genetic medicine platforms. uniQure was originally founded in the Netherlands under the name Amsterdam Molecular Therapeutics, before evolving into uniQure N.V. and expanding its operational footprint into the United States. Today, its corporate and operating structure is transatlantic, with key activities in Amsterdam and Lexington, Massachusetts. The company’s core business is based on gene therapy, primarily using adeno-associated virus (AAV) vectors to deliver therapeutic genetic material directly into target cells. uniQure is still largely a clinical-stage biotechnology company rather than a mature commercial pharma group, and its value proposition is concentrated in a relatively small number of high-impact programs. Its lead asset is AMT-130, a gene therapy candidate for Huntington’s disease, which is widely viewed as the company’s most strategically important program. uniQure is also advancing other rare-disease programs, including Fabry disease, reinforcing a strategy focused on genetically defined disorders where a one-time or long-acting intervention could create meaningful clinical and commercial value. From a competitive standpoint, uniQure is one of the earlier European pioneers in gene therapy, but it operates in a highly competitive field that includes specialized biotech companies pursuing in vivo and ex vivo genetic medicines. Its competitive edge comes from its long-standing scientific expertise, its clinical and regulatory experience, and its ability to work across the full gene-therapy value chain. The company also emphasizes its manufacturing presence in Lexington, Massachusetts, which is strategically important because gene therapy requires sophisticated process control, quality systems, and scalable supply capabilities. Geographically, the business is anchored mainly in the United States and the Netherlands, with research, development, manufacturing, and corporate functions distributed across those two hubs. Recent company updates in 2025 and early 2026 have centered on clinical and regulatory progress for AMT-130 and continued development of the Fabry program. uniQure also highlighted a stronger cash position following financing activity, an important factor for a biotech with significant R&D spending needs. For investors, the stock remains a classic high-risk, high-reward development story: upside is tied to clinical success, regulatory acceptance, and eventual commercialization, while downside risk remains meaningful if trial data, FDA interactions, or manufacturing execution fall short. In the context of SEC Form 4 insider transactions, QURE should therefore be analyzed primarily as a NASDAQ-listed U.S.-market biotech with binary catalysts and substantial pipeline dependence.